Revenue Breakdown
Composition ()
No data
Revenue Streams
Redhill Biopharma Ltd (RDHL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial operations, accounting for 55.4% of total sales, equivalent to $7.10M. Another important revenue stream is Research and Development. Understanding this composition is critical for investors evaluating how RDHL navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Redhill Biopharma Ltd maintains a gross margin of 60.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -107.33%, while the net margin is -101.32%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RDHL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RDHL competes directly with industry leaders such as QNRX and PCSA. With a market capitalization of $4.75M, it holds a significant position in the sector. When comparing efficiency, RDHL's gross margin of 60.60% stands against QNRX's N/A and PCSA's N/A. Such benchmarking helps identify whether Redhill Biopharma Ltd is trading at a premium or discount relative to its financial performance.
